uniQure에 대한 매도 수량은 투자자에게 uniQure의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

uniQure (NASDAQ:QURE) 주식, 공매도 수량 보고

uniQure

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Earnings

Equities

News

Eurozone

Intraday Update

Markets

Trading Ideas

CMRX

CPIX

CRVO

QURE

YEXT

미국 주식은 미국 동부 시간 오후 2시에 혼조세를 보였으며, S&amp;P 500 지수는 화요일 약 0.1% 하락했다. 다우 지수는 0.02% 하락한 44,393.25로 거래되었고, 나스닥 지수는 0.03% 상승한 19,743.54로 거래되었다. S&amp;P 500 지수 또한 0.06% 하락하여 6,049.44로 거래되었다.

뉴욕 오후 2시 시황: S&amp;P 500 소폭 하락, 오토존, 부진한 1분기 실적 발표

uniQure NV

Mizuho analyst Uy Ear maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Neutral and raises the price target from $7 to $20.

Price Target

Analyst Ratings

Mizuho Maintains Neutral on uniQure, Raises Price Target to $20

WIIM

UniQure shares are trading higher after Stifel maintained a Buy rating on the stock and raised its price target from $12 to $32.

Stifel analyst Paul Matteis maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and raises the price target from $12 to $32.

Stifel Maintains Buy on uniQure, Raises Price Target to $32

Goldman Sachs analyst Salveen Richter maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Neutral and raises the price target from $9 to $20.

Goldman Sachs Maintains Neutral on uniQure, Raises Price Target to $20

UniQure shares are trading higher after RBC Capital and Leerink Partners maintained Outperform ratings on the stock and raised their respective price targets.

Leerink Partners maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Outperform and raises the price target from $26 to $44.

Leerink Partners Maintains Outperform on uniQure, Raises Price Target to $44

Guggenheim analyst Debjit Chattopadhyay reiterates uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) from Buy to Buy.

Reiteration

Guggenheim Reiterates Buy on uniQureto Buy

RBC Capital analyst Luca Issi maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Outperform and raises the price target from $14 to $20.

RBC Capital Maintains Outperform on uniQure, Raises Price Target to $20

U.S. stocks traded mixed toward the end of trading, with the S&amp;P 500 falling by around 0.1% on Tuesday.
The Dow traded down 0.02% to 44,393.25 while the NASDAQ rose 0.03% to 19,743.54. The S&amp;P 500 also fell, dropping, 0.06% to 6,049.44.
Check This Out: <a href="https://www.benzinga.com/24/12/42413544/how-to-earn-500-a-month-from-macys-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Macy&#8217;s Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 2.3% on Tuesday.
In trading on Tuesday, real estate shares fell by 1%.
Top Headline
On Tuesday, AutoZone, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZO#NYSE">AZO</a>) reported weaker-than-expected earnings and sales results for its fiscal first quarter.
The company posted earnings per share of $32.52, missing the Street view of $33.76. Quarterly revenues of $4.28 billion (+2.1% year over year) missed the analyst consensus of $4.30 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Chimerix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares shot up 213% to $2.71 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.</li>
<li>Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) got a boost, surging 94% to $2.4001 after the company announced the FDA has approved its supplemental new drug application for acetadote.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares were also up, gaining 129% to $16.71 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares dropped 77% to $2.34 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.</li>
<li>Shares of Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) were down 17% to $7.07 following third-quarter results.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) was down, falling 46% to $1.52. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.</li>
</ul>
Commodities In commodity news, oil traded up 0.7% to $68.84 while gold traded up 1.2% at $2,718.80.
Silver traded up 0.4% to $32.73 on Tuesday, while copper fell 0.1% to $4.2730.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.52%, Germany's DAX fell 0.08% and France's CAC 40 fell 1.14%. Spain's IBEX 35 Index fell 0.38%, while London's FTSE 100 fell 0.86%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

S&P 500 Edges Lower; AutoZone Posts Downbeat Earnings

U.S. stocks traded mostly higher midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday.
The Dow traded up 0.02% to 44,412.05 while the NASDAQ rose 0.25% to 19,786.14. The S&amp;P 500 also rose, gaining, 0.07% to 6,057.30.
Check This Out: <a href="https://www.benzinga.com/24/12/42413544/how-to-earn-500-a-month-from-macys-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Macy&#8217;s Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 2.5% on Tuesday.
In trading on Tuesday, real estate shares fell by 0.9%.
Top Headline
Ollie's Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) shares jumped over 14% on Tuesday after the company released third-quarter results.
The company reported third-quarter adjusted earnings per share of 58 cents, beating the street view of 57 cents. Quarterly sales of $517.43 million (+7.8%) beat the analyst consensus of $517.36 million. The increase in net sales was the result of new store unit growth.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Chimerix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares shot up 207% to $2.67 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.</li>
<li>Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) got a boost, surging 93% to $2.3888 after the company announced the FDA has approved its supplemental new drug application for acetadote.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares were also up, gaining 130% to $16.78 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares dropped 78% to $2.2250 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.</li>
<li>Shares of Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) were down 18% to $7.01 following third-quarter results.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) was down, falling 47% to $1.50. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.</li>
</ul>
Commodities In commodity news, oil traded up 0.8% to $68.94 while gold traded up 1.2% at $2,718.90.
Silver traded up 0.3% to $32.710 on Tuesday, while copper fell 0.3% to $4.2635.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.52%, Germany's DAX fell 0.08% and France's CAC 40 fell 1.14%. Spain's IBEX 35 Index fell 0.38%, while London's FTSE 100 fell 0.86%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Commodities

OLLI

Gold Gains Over 1%; Ollie's Bargain Outlet Shares Jump After Q3 Earnings

HC Wainwright &amp; Co. analyst Patrick Trucchio reiterates uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Buy and maintains $25 price target.

HC Wainwright & Co. Reiterates Buy on uniQure, Maintains $25 Price Target

Raymond James analyst Danielle Brill upgrades uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) from Outperform to Strong Buy and raises the price target from $20 to $52.

Upgrades

Raymond James Upgrades uniQure to Strong Buy, Raises Price Target to $52

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Tuesday.
Shares of United Natural Foods, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNFI#NYSE">UNFI</a>) rose sharply during Tuesday's session following better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/UNFI/earnings">raised its FY25 guidance.</a>
United Natural Foods posted adjusted earnings of 16 cents per share, compared to market estimates for a loss of 1 cent per share. The company's quarterly sales came in at $7.87 billion versus expectations of $7.61 billion.
United Natural Foods shares surged 29% to $31.82 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares jumped 105.6% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
<li>NewAmsterdam Pharma Company N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAMS#NASDAQ">NAMS</a>) gained 35.5% to $25.10 after the company announced topline data from its Phase 3 BROADWAY trial of Obicetrapib.</li>
<li>Absci Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>) gained 21.5% to $3.8999.</li>
<li>Byrna Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYRN#NASDAQ">BYRN</a>) surged 16.7% to $22.09 as the company announced preliminary fiscal fourth quarter record revenues of $28.0 million.</li>
<li>Rigetti Computing, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) gained 15.1% to $5.12. Quantum Machines and Rigetti announced successful AI-powered calibration of a Quantum Computer.</li>
<li>Solaris Energy Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEI#NYSE">SEI</a>) gained 15.1% to $29.65. Solaris Energy Infrastructure priced its public offering of 6.5 million Class A shares at $24.75 each for net proceeds of $156 million.</li>
<li>Ollie&#8217;s Bargain Outlet Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) jumped 14.7% to $111.48 after the company reported better-than-expected third-quarter financial results.</li>
<li>MoneyLion Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ML#NYSE">ML</a>) gained 14.7% to $88.30 after the company announced an agreement to be acquired for $82 per share in cash for a total value of approximately $1 billion.</li>
<li>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>) rose 13.5% to $61.54 r after the company unveiled &#8220;Alaska Accelerate&#8221;, a strategy to boost profitability and its global footprint. Additionally, the company issued a strong FY25 outlook and plans for nonstop routes to Tokyo and Seoul from Seattle.</li>
<li>Nebius Group N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIS#NASDAQ">NBIS</a>) gained 6.2% to $33.94.</li>
<li>Super Group (SGHC) Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SGHC#NYSE">SGHC</a>) rose 5.9% to $7.01. The company issued business update as 2024 closes.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) climbed 5.5% to $121.32 after the company inked a Business Transfer Agreement to acquire the Happay Expense Management Platform from CRED for an undisclosed amount.</li>
<li>Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) gained 4.6% to $183.45.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Movers

ABSI

BYRN

GOOGL

MMYT

NAMS

NBIS

RGTI

SGHC

UNFI

United Natural Foods Posts Upbeat Results, Joins Alphabet, Ollie's Bargain, MoneyLion And Other Big Stocks Moving Higher On Tuesday

Cantor Fitzgerald analyst Kristen Kluska maintains uniQure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) with a Overweight and raises the price target from $28 to $58.

Cantor Fitzgerald Maintains Overweight on uniQure, Raises Price Target to $58

U.S. stocks traded mixed this morning, with the Dow Jones index falling around 150 points on Tuesday.
Following the market opening Tuesday, the Dow traded down 0.36% to 44,242.81 while the NASDAQ rose 0.43% to 19,820.91. The S&amp;P 500 also fell, dropping, 0.01% to 6,052.43.
Check This Out: <a href="https://www.benzinga.com/24/12/42413544/how-to-earn-500-a-month-from-macys-stock-ahead-of-q3-earnings">How To Earn $500 A Month From Macy&#8217;s Stock Ahead Of Q3 Earnings</a>
Leading and Lagging Sectors Communication services shares jumped by 2.3% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.1%.
Top Headline
Oracle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) posted weaker-than-expected earnings and sales results for its second quarter on Monday.
The company reported second-quarter revenue of $14.06 billion, up 9% year-over-year. The revenue total missed a Street consensus estimate of $14.11 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Chimerix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) shares shot up 172% to $2.36 after the company announced it will submit dordaviprone for accelerated approval to the FDA for patients with recurrent H3 K27M-mutant diffuse glioma.</li>
<li>Shares of Cumberland Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPIX#NASDAQ">CPIX</a>) got a boost, surging 112% to $2.6400 after the company announced the FDA has approved its supplemental new drug application for acetadote.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares were also up, gaining 104% to $15.00 after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.</li>
</ul>
Equities Trading DOWN
<ul>
<li>CervoMed Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVO#NASDAQ">CRVO</a>) shares dropped 75% to $2.54 after the company announced its Phase 2b trial of Neflamapimod failed to meet its key endpoints for the treatment of dementia.</li>
<li>Shares of Biora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) were down 44% to $0.7499.</li>
<li>MEDIROM Healthcare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRM#NASDAQ">MRM</a>) was down, falling 41% to $1.65. MEDIROM Healthcare priced its $5 million public offering of 2.86 million American Depositary Shares at $1.75 per ADS.</li>
</ul>
Commodities In commodity news, oil traded up 0.1% to $68.40 while gold traded up 1% at $2,712.20.
Silver traded up 0.4% to $32.750 on Tuesday, while copper fell 0.6% to $4.2500.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.2%, Germany's DAX rose 0.2% and France's CAC 40 fell 0.6%. Spain's IBEX 35 Index fell 0.1%, while London's FTSE 100 fell 0.6%.
Asia Pacific Markets
Asian markets closed mixed on Monday, with Japan's Nikkei 225 gaining 0.18%, Hong Kong's Hang Seng Index gaining 2.76%, China's Shanghai Composite Index falling 0.05% and India's BSE Sensex falling 0.25%.
Economics
U.S. nonfarm business sector labor productivity increased by 2.2% in the third quarter, in-line with the preliminary reading.&nbsp;&nbsp;&nbsp;&nbsp;
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42412458/amazon-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday">Amazon To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

BIOR

ORCL

Dow Falls 150 Points; Oracle Posts Downbeat Results

uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) shares are rising following a significant development in its <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42409488/uniqure-announces-alignment-with-fda-on-key-elements-of-accelerated-approval-pathway-for-amt-130-i" rel="noreferrer noopener">efforts to treat Huntington&#8217;s disease</a>.
The company has made a key breakthrough with its treatment, AMT-130. The company announced that the FDA has agreed on important elements for an accelerated approval pathway for AMT-130, a potential therapy aimed at slowing the disease&#8217;s progression.
The FDA&#8217;s decision followed discussions regarding data from ongoing Phase I/II clinical studies. The FDA has confirmed that the data, compared to a natural history control, can be used for the Biologics License Application (BLA), bypassing the need for additional pre-submission studies.
Huntington&#8217;s disease is a rare, inherited neurodegenerative disorder that causes progressive motor dysfunction, cognitive decline, and behavioral changes.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42408217/us-stocks-to-open-lower-as-traders-await-slew-of-data-us-listed-chinese-stocks-in-focus-following-stimulus-pledge" rel="noreferrer noopener">US Stocks Likely To Open Lower As Traders Await Slew Of Data: US-Listed Chinese Stocks In Focus Following Stimulus Pledge</a>
This latest agreement marks a crucial milestone for the Huntington&#8217;s disease community, as AMT-130 could soon become a groundbreaking therapy.
The FDA also acknowledged reductions in neurofilament light chain (NfL), a biomarker of neurodegeneration, as supportive evidence of the therapy&#8217;s potential benefits.
uniQure continues its efforts in advancing AMT-130, with BLA readiness activities underway and plans to engage further with the FDA in early 2025.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, QURE stock has gained over 2% in the past year. Investors can gain exposure to the stock via Virtus LifeSci Biotech Clinical Trials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBC#NYSE">BBC</a>).
Price Action: QURE shares are trading higher by 87.8% to $13.70 in the premarket session on Tuesday.
Read Next:
<ul>
<li><a href="http://trump's%20deregulation%20efforts%20to%20benefit%20energy,%20oil%20and%20gas%20sectors,%20while%20ai%20frenzy%20will%20boost%20faang%20stocks%20and%20nvidia,%20says%20fintech%20insider/" target="_blank" rel="noreferrer noopener">Trump&#8217;s Deregulation Efforts To Benefit Energy, Oil And Gas Sectors, While AI Frenzy Will Boost FAANG Stocks And Nvidia, Says Fintech Insider</a></li>
</ul>
Photo via Shutterstock.

General

Why Is uniQure Stock Skyrocketing On Tuesday?

UniQure shares are trading higher after the company announced an agreement with the FDA on key elements of an accelerated pathway for AMT-130.

LLY: 1.5% &#x7C; <a href="https://www.benzinga.com//node/42402861">Eli Lilly Reports Results From Phase 3 BRUIN CLL-321 Trial Evaluating Pirtobrutinib; Study's Primary Endpoint Of Progression-Free Survival Was Met At Primary Analysis; announces $15B share repurchase program, 15% dividend increase</a>
&nbsp;
ORCL: -10% &#x7C; <a href="https://www.benzinga.com//node/42399913">Oracle shares are trading lower following worse-than-expected Q2 financial results.</a>
&nbsp;
QURE: 105% &#x7C; <a href="https://www.benzinga.com//node/42409562">uniQure Reaches Agreement With FDA On Key Elements Of An Accelerated Approval Pathway For AMT-130</a>

Market-Moving news for December 10th

As part of uniQure's Regenerative Medicine Advanced Therapy (RMAT) Type B meeting held in late November, the FDA agreed that data from the ongoing Phase I/II studies, compared to a natural history external control, may serve as the primary basis for a BLA submission under the Accelerated Approval pathway, avoiding the need for an additional pre-submission study.&nbsp;
The FDA also agreed that cUHDRS may be used as an intermediate clinical endpoint and that reductions in neurofilament light chain (NfL) measured in cerebrospinal fluid (CSF) may serve as supportive evidence of therapeutic benefit in the application for accelerated approval.

uniQure Reaches Agreement With FDA On Key Elements Of An Accelerated Approval Pathway For AMT-130

Biotech

Health Care

uniQure Has Dosed The First Patient In GenTLE Phase 1/2a Trial Of AMT-260 For Refractory Mesial Temporal Lobe Epilepsy

Wells Fargo upgraded uniQure (QURE) to Overweight from Equal Weight with a price target of $35, up from $14. Published first on TheFly – the ultima...

uniQure upgraded to Overweight from Equal Weight at Wells Fargo

Raymond James, Cantor bullish on uniQure following FDA update

William Blair analyst Sami Corwin has maintained their bullish stance on QURE stock, giving a Buy rating today. Sami Corwin has given his Buy ratin...

uniQure's AMT-130 Gene Therapy for Huntington's Disease: A Promising Pathway to Accelerated Approval

uniQure's AMT-130: A Bold Step For Huntington's, But Not Without Hurdles

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Notable analyst calls this week: AMD, Adobe and Utilities stocks among top picks

Stifel analyst Paul Matteis raised the firm's price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is "com...

uniQure price target raised to $32 from $12 at Stifel

Mizuho raised the firm's price target on uniQure (QURE) to $20 from $7 and keeps a Neutral rating on the shares. The firm cites increased confidenc...

uniQure price target raised to $20 from $7 at Mizuho

Bullish option flow detected in uniQure (QURE) with 6,527 calls trading, 2x expected, and implied vol increasing over 14 points to 82.58%. Jan-25 1...

uniQure call volume above normal and directionally bullish

In a report released yesterday, Uy Ear from Mizuho Securities maintained a Hold rating on uniQure (QURE – Research Report), with a price target of ...

Mizuho Securities Reaffirms Their Hold Rating on uniQure (QURE)

ADBE

ANAB

AUPH

AVGO

BGNE

CLRB

CRSP

EBAY

EYEN

GOOG

HOOD

JAGX

PINS

PTCT

PYPL

SCHW

SOFI

TASK

TMHC

VMEO

VRTX

XFOR

Press Releases

Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington's Disease

uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

uniQure Announces Dosing of First Patient in Phase I/II Clinical Trial of AMT-162 for the Treatment SOD1-ALS

uniQure Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy

Comments

uniQure

매도 수량

uniQure (NASDAQ:QURE) 주식, 공매도 수량 보고

뉴스

파트너 / 기고자

벤징가 글로벌